File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Predicting HBsAg clearance responses during ARC-520 RNA interference (RNAi) therapy based on HBsAg epitope profile analysis

TitlePredicting HBsAg clearance responses during ARC-520 RNA interference (RNAi) therapy based on HBsAg epitope profile analysis
Authors
Walsh, RYuen, LHammond, RDeerain, JGiven, BSchluep, TYuen, MFChan, HLYLai, CLHamilton, JLau, JYFerrari, CGish, RGLocarnini, SA
Issue Date2016
PublisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jhep
Citation
The International Liver Congress™ 2016 - The 51st Annual Meeting of the European Association for the Study of the Liver (EASL 2016), Barcelona, Spain, 13-17 April, 2016. In Journal of Hepatology, 2016, v. 64 n. 2 suppl., p. S602, abstract no. FRI-144 How to Cite?
DOI: http://dx.doi.org/10.1016/S0168-8278(16)01112-0
AbstractBACKGROUND AND AIMS: Functional cure in chronic hepatitis B requires HBV DNA negativity, HBsAg loss and anti-HBs seroconversion. ARC-520 RNAi drug therapy targets cccDNA derived mRNA, including the full-length HBsAg transcript. Using a 19plex anti-HBs panel to map HBsAg epitopes, we have developed a predictive algorithm of an HBsAg clearance profile in patients undergoing HBsAg loss during tenofovir therapy, defined as reduced recognition at loop 1 and loop 2 HBsAg “a” determinant epitopes. Complimentary to this, we have developed assays to detect co-existing complexed anti-HBs (with HBsAg), and analysed the ARC- 520 cohorts with the aim of evaluating the impact of RNAi therapy on HBsAg loss, the identification of an HBsAg clearance profile and the development of co-existing anti-HBs …
DescriptionPoster Presentations - Predicting HBsAg clearance responses during ARC-520 RNA interference: no. FRI-144
Persistent Identifierhttp://hdl.handle.net/10722/234186
ISSN
0168-8278
2021 Impact Factor: 30.083
2020 SCImago Journal Rankings: 7.112
ISI Accession Number ID
WOS:000398715800297

 

DC FieldValueLanguage
dc.contributor.authorWalsh, R-
dc.contributor.authorYuen, L-
dc.contributor.authorHammond, R-
dc.contributor.authorDeerain, J-
dc.contributor.authorGiven, B-
dc.contributor.authorSchluep, T-
dc.contributor.authorYuen, MF-
dc.contributor.authorChan, HLY-
dc.contributor.authorLai, CL-
dc.contributor.authorHamilton, J-
dc.contributor.authorLau, JY-
dc.contributor.authorFerrari, C-
dc.contributor.authorGish, RG-
dc.contributor.authorLocarnini, SA-
dc.date.accessioned2016-10-14T06:59:41Z-
dc.date.available2016-10-14T06:59:41Z-
dc.date.issued2016-
dc.identifier.citationThe International Liver Congress™ 2016 - The 51st Annual Meeting of the European Association for the Study of the Liver (EASL 2016), Barcelona, Spain, 13-17 April, 2016. In Journal of Hepatology, 2016, v. 64 n. 2 suppl., p. S602, abstract no. FRI-144-
dc.identifier.issn0168-8278-
dc.identifier.urihttp://hdl.handle.net/10722/234186-
dc.descriptionPoster Presentations - Predicting HBsAg clearance responses during ARC-520 RNA interference: no. FRI-144-
dc.description.abstractBACKGROUND AND AIMS: Functional cure in chronic hepatitis B requires HBV DNA negativity, HBsAg loss and anti-HBs seroconversion. ARC-520 RNAi drug therapy targets cccDNA derived mRNA, including the full-length HBsAg transcript. Using a 19plex anti-HBs panel to map HBsAg epitopes, we have developed a predictive algorithm of an HBsAg clearance profile in patients undergoing HBsAg loss during tenofovir therapy, defined as reduced recognition at loop 1 and loop 2 HBsAg “a” determinant epitopes. Complimentary to this, we have developed assays to detect co-existing complexed anti-HBs (with HBsAg), and analysed the ARC- 520 cohorts with the aim of evaluating the impact of RNAi therapy on HBsAg loss, the identification of an HBsAg clearance profile and the development of co-existing anti-HBs …-
dc.languageeng-
dc.publisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jhep-
dc.relation.ispartofJournal of Hepatology-
dc.rights© 2016. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/-
dc.titlePredicting HBsAg clearance responses during ARC-520 RNA interference (RNAi) therapy based on HBsAg epitope profile analysis-
dc.typeConference_Paper-
dc.identifier.emailYuen, MF: mfyuen@hku.hk-
dc.identifier.emailLai, CL: hrmelcl@hkucc.hku.hk-
dc.identifier.authorityYuen, MF=rp00479-
dc.identifier.authorityLai, CL=rp00314-
dc.identifier.doi10.1016/S0168-8278(16)01112-0-
dc.identifier.hkuros267700-
dc.identifier.volume64-
dc.identifier.issue2 suppl.-
dc.identifier.spageS602, abstract no. FRI-144-
dc.identifier.epageS602, abstract no. FRI-144-
dc.identifier.isiWOS:000398715800297-
dc.publisher.placeThe Netherlands-
dc.identifier.issnl0168-8278-

Export via OAI-PMH Interface in XML Formats

OR

Export to Other Non-XML Formats